<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101715200</journal-id>
<journal-id journal-id-type="pubmed-jr-id">46993</journal-id>
<journal-id journal-id-type="nlm-ta">Curr Opin Physiol</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr Opin Physiol</journal-id>
<journal-title-group>
<journal-title>Current opinion in physiology</journal-title>
</journal-title-group>
<issn pub-type="epub">2468-8673</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30123852</article-id>
<article-id pub-id-type="pmc">6091224</article-id>
<article-id pub-id-type="doi">10.1016/j.cophys.2017.12.007</article-id>
<article-id pub-id-type="manuscript">NIHMS930505</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Dravet Syndrome: A Sodium Channel Interneuronopathy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Catterall</surname>
<given-names>William A.</given-names>
</name>
</contrib>
<aff id="A1">Department of Pharmacology, University of Washington, Seattle, WA 98195-7280 USA</aff>
</contrib-group>
<author-notes>
<fn fn-type="COI-statement" id="FN2">
<p id="P26">The author declares no conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>26</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>23</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>4</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>4</month>
<year>2019</year>
</pub-date>
<volume>2</volume>
<fpage>42</fpage>
<lpage>50</lpage>
<!--elocation-id from pubmed: 10.1016/j.cophys.2017.12.007-->
<self-uri xlink:href="https://www.sciencedirect.com/science/article/pii/S2468867317300305?via%3Dihub"></self-uri>
<abstract id="ABS1">
<p id="P1">Dravet Syndrome is a devastating childhood epilepsy disorder with high incidence of premature death plus comorbidities of ataxia, circadian rhythm disorder, impaired sleep quality, autistic-like social-interaction deficits and severe cognitive impairment. It is primarily caused by heterozygous loss-of-function mutations in the <italic>SCN1A</italic> gene that encodes brain voltage-gated sodium channel type-1, termed Na<sub>V</sub>1.1. Here I review experiments on mouse genetic models that implicate specific loss of sodium currents and action potential firing in GABAergic inhibitory interneurons as the fundamental cause of Dravet Syndrome. The resulting imbalance of excitatory to inhibitory neurotransmission in neural circuits causes both epilepsy and co-morbidities. Promising therapeutic approaches involving atypical sodium channel blockers, novel drug combinations, and cannabidiol give hope for improved outcomes for Dravet Syndrome patients.</p>
</abstract>
<kwd-group>
<kwd>Epilepsy</kwd>
<kwd>autism</kwd>
<kwd>cognitive deficit</kwd>
<kwd>sodium channels</kwd>
<kwd>interneurons</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>